Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 6:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pharmacokinetics Clear all
Withdrawn Phase 4 Interventional

Study Comparing Blood Levels of ReFacto and Advante in Hemophilia A

NCT00168051
View directory record Official record
Conditions
Hemophilia A
Interventions
ReFacto, Advante
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
4
States / cities
Washington D.C., District of Columbia • Atlanta, Georgia • Iowa City, Iowa + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 24, 2018 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Results available

A Phase 1 Study of Intraoperative Administration of CA-008 for the Correction of Hallux Valgus Deformity

NCT03307837
View directory record Official record
Conditions
Hallux Valgus Deformity
Interventions
CA-008, Placebo
Drug
Lead sponsor
Concentric Analgesics
Industry
Eligibility
18 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Pasadena, California
Source: ClinicalTrials.gov public record
Updated Jun 29, 2021 · Synced Jul 23, 2026, 6:23 AM EDT
Withdrawn Phase 1Phase 2 Interventional

A Study of IMPT-514 in Active Refractory Lupus Nephritis (LN) and Systemic Lupus Erythematosus (SLE)

NCT06153095
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Lupus Nephritis
Interventions
IMPT-514
Biological
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
3
States / cities
Los Angeles, California • San Francisco, California • Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 9, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate How Multiple Oral Doses of AZD2389 Affect the Pharmacokinetics of Midazolam, Caffeine, and Bupropion in Healthy Participants

NCT06973005
View directory record Official record
Conditions
Advanced Chronic Liver Disease, Healthy Participants
Interventions
AZD2389, Midazolam, Caffeine, Bupropion
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Brooklyn, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 23, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Idasanutlin Monotherapy in Participants With Hydroxyurea-Resistant/Intolerant Polycythemia Vera

NCT03287245
View directory record Official record
Conditions
Polycythemia Vera
Interventions
Idasanutlin
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
5
States / cities
Phoenix, Arizona • Kansas City, Kansas • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2021 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MK-6194 Site of Injection Study in Healthy Adult Participants (MK-6194-013)

NCT06649877
View directory record Official record
Conditions
Healthy
Interventions
MK-6194
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
South Miami, Florida
Source: ClinicalTrials.gov public record
Updated Oct 20, 2024 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

SL-11047 in Treating Patients With Relapsed or Refractory Lymphoma

NCT00293488
View directory record Official record
Conditions
Lymphoma
Interventions
polyamine analogue PG11047
Drug
Lead sponsor
Progen Pharmaceuticals
Industry
Eligibility
18 Years to 120 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 22, 2016 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

MAD in Cancer Patients: Safety of BMS-582664 in Patients With Advanced or Metastatic Solid Tumors

NCT00207103
View directory record Official record
Conditions
Tumors, Neoplasm Metastasis
Interventions
Brivanib, Brivanab
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
3
States / cities
Santa Monica, California • Indianapolis, Indiana • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 3, 2008 · Synced Jul 23, 2026, 6:23 AM EDT
Terminated Phase 1 Interventional Results available

Safety, Tolerability, PK, PD, and Efficacy of AMG 427 in Subjects With Relapsed/Refractory Acute Myeloid Leukemia

NCT03541369
View directory record Official record
Conditions
Relapsed/Refractory Acute Myeloid Leukemia (AML)
Interventions
AMG 427
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
7
States / cities
Duarte, California • Evanston, Illinois • Baltimore, Maryland + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Pharmacokinetics of Two Fatty Acid Ketone Esters

NCT05686083
View directory record Official record
Conditions
Pharmacokinetics
Interventions
C6 ketone di-ester, Novel ketone di-ester
Dietary Supplement
Lead sponsor
BHB Therapeutics, Ireland LTD
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 19, 2023 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Apalutamide in Participants With Severe Hepatic Impairment Compared With Participants With Normal Hepatic Function

NCT04154774
View directory record Official record
Conditions
Hepatic Impairment
Interventions
Apalutamide
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 80 Years · Male only
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
4
States / cities
Homestead, Florida • Orlando, Florida • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

Single-Dose Study Of PF-04603629 In Type 2 Diabetic Subjects

NCT00638313
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-04603629
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Phoenix, Arizona • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2009 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer

NCT01415960
View directory record Official record
Conditions
Prostate Cancer
Interventions
Leuprolide acetate 22.5 mg depot, GP-Pharm SA
Drug
Lead sponsor
GP-Pharm
Industry
Eligibility
18 Years and older · Male only
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
25
States / cities
San Diego, California • Daytona Beach, Florida • Ocala, Florida + 22 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Multiple Ascending Dose Study of TMP-301 in Healthy Subjects

NCT06025396
View directory record Official record
Conditions
Cocaine Use Disorder, Substance Use Disorders, Healthy Volunteers
Interventions
Cohort 1 - TMP-301, Placebo, Cohort 2 - TMP-301, Cohort 3 - TMP-301, Cohort 4 - TMP-301
Drug
Lead sponsor
Tempero Bio, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 28, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Safety, Tolerability, and Drug Levels of Danicamtiv in Healthy Japanese and Caucasian Participants

NCT05806359
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Danicamtiv, Placebo
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated May 22, 2024 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 3 Interventional Results available

Evaluation of VX 445/TEZ/IVA in Cystic Fibrosis Subjects 6 Through 11 Years of Age

NCT03691779
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
ELX/TEZ/IVA, IVA
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
13
States / cities
Orange, California • Aurora, Colorado • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2021 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3832479 (LY-CoV016) in Healthy Participants 1

NCT04611789
View directory record Official record
Conditions
Healthy
Interventions
LY3832479, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 60 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated Dec 5, 2021 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Blood and Urine Drug Levels of Fostamatinib Disodium (FosD) in Healthy Japanese and White Subjects

NCT01167868
View directory record Official record
Conditions
Healthy
Interventions
FosD, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
20 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment

NCT05624710
View directory record Official record
Conditions
Renal Insufficiency, Kidney Diseases
Interventions
INCB054707
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 80 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
3
States / cities
Tustin, California • Orlando, Florida • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Not applicable Interventional

Caspofungin Acetate in Treating Children With Fever and Neutropenia

NCT00020527
View directory record Official record
Conditions
Fever, Sweats, and Hot Flashes, Infection, Kidney Cancer, Leukemia, Lymphoma, Neuroblastoma, Neutropenia, Sarcoma
Interventions
caspofungin acetate
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years to 17 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
5
States / cities
Washington D.C., District of Columbia • Baltimore, Maryland • Bethesda, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2013 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

A Phase I Study of BMS-690514 in Combination With Paclitaxel and Carboplatin

NCT00420186
View directory record Official record
Conditions
Cancer (Solid Tumors)
Interventions
BMS-690514
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
2
States / cities
Buffalo, New York • Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 29, 2016 · Synced Jul 23, 2026, 6:23 AM EDT
Terminated Phase 1 Interventional

Study of Intravenous RXDX-107 in Patients With Solid Tumors

NCT02548390
View directory record Official record
Conditions
Solid Tumor
Interventions
RXDX-107
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
3
States / cities
Sarasota, Florida • Baltimore, Maryland • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2019 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional

Single Cohort 4-period Study to Assess Pharmacokinetics of Metformin Alone and in Combination With Ranolazine

NCT01546597
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Metformin, Ranolazine
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
30 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2012 · Synced Jul 23, 2026, 6:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

To Evaluate the Safety, and Pharmacokinetics of Parscaclisib in Participants With Normal Renal Function and Renal Impairment.

NCT04831996
View directory record Official record
Conditions
Advanced Malignancies
Interventions
parsaclisib
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years to 82 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Tustin, California • Hialeah, Florida • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2022 · Synced Jul 23, 2026, 6:23 AM EDT